Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Hussey, Elizabeth K ^a   Kapur, Anita ^a   O'Connor Semmes, Robin ^a   Tao, Wenli ^a   Rafferty, Bryan ^a   Polli, Joseph W ^a   James, Charles D ^b   Dobbins, Robert L ^a  

^a GLAXOSMITHKLINE   (United States)

^b Tandem Labs   (United States)

Author keywords

Metformin; Pharmacokinetics; Remogliflozin etabonate; SGLT2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

CREATININE; DRUG METABOLITE; GLUCOSE; HEMOGLOBIN A1C; LACTIC ACID; METFORMIN; REMOGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; PRODRUG; PYRAZOLE DERIVATIVE; SLC5A2 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DIABETIC PATIENT; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE SPASM; NECK PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; TREATMENT DURATION; URINARY EXCRETION; WOUND; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; URINE; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PRODRUGS; PYRAZOLES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84880645404     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-25     Document Type: Article

References (39)

1. DCCT Research Group The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995, 44:968-983. DCCT Research Group.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117. 10.1016/0168-8227(95)01064-K, 7587918.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000, 321:405-412.
4. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study (UKPDS) Group.
5. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
6. American Diabetes Association Standards of medical care in diabetes. PhD Thesis 2007, American Diabetes Association.
7. Nathan D, Buse J, Davidson M, Heine R, Holman R, Sherwin R, Zinman B. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006, 49:1711-1721. 10.1007/s00125-006-0316-2, 16802130.
8. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996, 30:359-371. 10.2165/00003088-199630050-00003, 8743335.
9. Graham GG, Punt J, Arora M, Day R, Doogue MP, Duopng JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011, 50:81-98. 10.2165/11534750-000000000-00000, 21241070.
10. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005, 28:601-631. 10.2165/00002018-200528070-00004, 15963007.
11. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008, 31:2086-2091. 10.2337/dc08-1171, 2571051, 18782901.
12. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: the fremantle diabetes study. Br J Clin Pharmacol 2001, 52:137-144. 10.1046/j.0306-5251.2001.01423.x, 2014521, 11488769.
13. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003, 163:2594-2602. 10.1001/archinte.163.21.2594, 14638559.
14. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994, 93:397-404. 10.1172/JCI116972, 293794, 8282810.
15. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007, 261:32-43. 10.1111/j.1365-2796.2006.01746.x, 17222166.
16. Handlon AL. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin Ther Pat 2005, 13:1531-1540.
17. Hussey E, Clark R, Amin D, Kipnes M, O'Connor-Semmes R, O'Driscoll E, Leong J, Murray S, Dobbins R, Layko D, et al. The single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus. J Clin Pharmacol 2010, 50:623-635. 10.1177/0091270009351879, 20056803.
18. Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJR. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol 2010, 50:636-646. 10.1177/0091270009352185, 20200268.
19. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009, 11:79-88. 10.1111/j.1463-1326.2008.00982.x, 19125776.
20. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007, 8:285-292.
21. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85:513-519. 10.1038/clpt.2008.250, 19129749.
22. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009, 85:520-526. 10.1038/clpt.2008.251, 19129748.
23. Asano T, Ogihara T, Katagiri H, Sakoda H, Ono H, Fujishiro M, Anai M, Kurihara H, Uchijima Y. Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr Med Chem 2004, 11:2717-2724. 10.2174/0929867043364360, 15544472.
24. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005, 21:31-38. 10.1002/dmrr.532, 15624123.
25. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007, 320:323-330.
26. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008, 62:1279-1284. 10.1111/j.1742-1241.2008.01829.x, 18705823.
27. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008, 327:268-276. 10.1124/jpet.108.140210, 18583547.
28. Sigafoos J, Bowers G, Castellino S, Culp AG, Wagner DS, Reese JM, Humphreys JE, Hussey EK, O'Connor-Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab Dispos 2012, 40:2090-2101. 10.1124/dmd.112.047258, 22851617.
29. Dobbins R, Kapur A, Kapitza C, O'Connor-Semmes R, Tao W, Hussey E. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SCLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients. Diabetes 2009, 58:1573-P.
30. Kapur A, O'Connor-Semmes R, Hussey E, Dobbins R, Tao W, Hompesch M, Nunez D. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus (T2DM). Diabetes 2009, 58:509-P.
31. Sung EY, Moore MP, Lunt H, Doogue M, Zhang M, Begg EJ. Do thiazide diuretics alter the pharmacokinetics of metformin in patients with type 2 diabetes already established on metformin?. Br J Clin Pharmacol 2009, 67:130-131. 10.1111/j.1365-2125.2008.03302.x, 2668094, 18823300.
32. Thurman J, Wiseman A. The patient with glomerulonephritis or vasculitis. Manual of Nephrology 2009, 140-153. Philadelphia: Lippincott Williams & Wilkins, Schrier RW, 7.
33. Saffar F, Aiache JM, Andre P. Influence of food on the disposition of the antidiabetic drug metformin in diabetic patients at steady-state. Methods Find Exp Clin Pharmacol 1995, 17:483-487.
34. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005, 44:721-729. 10.2165/00003088-200544070-00004, 15966755.
35. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987, 15:657-680. 10.1007/BF01068419, 3450848.
36. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990, 28:72-78.
37. Hollander M, Wolfe DA. Nonparametric Statistical Methods 1973, New York: Wiley.
38. Del Prato S, Felton A-M, Munro N, Nesto R, Zimmet P, Zinman B, on behalf of the Global Partnership for Effective Diabetes Management Improving glucose management: ten steps to get more patients with type 2 diabetes to goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2005, 59:1345-1355. 10.1111/j.1742-1241.2005.00674.x, 16236091, on behalf of the Global Partnership for Effective Diabetes Management.
39. Polli JW, Humphreys JE, Harmon KA, Webster LO, Reese MJ, MacLauchlin CC. Assessment of remogliflozin etabonate, a sodium-dependent glucose co-transporter-2 inhibitor, as a perpetrator of clinical drug interactions: a study on drug transporters and metabolic enzymes. J Diabetes Metab 2012, 3:5. http://dx.doi.org/10.4172/2155-6156.1000200.